No more than 15 authors can be listed.Please ensure the authors are listed in the right order.If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.
ANCA-negative eosinophilic granulomatosis with polyangiitis (EGPA) accounts for 60-70% of EGPA cases, mainly involving the lungs and heart with impaired pulmonary ventilation. Corticosteroids as first-line therapy are limited by steroid dependence, adverse reactions and poor symptom control in some patients. Mepolizumab, an anti-interleukin-5 monoclonal antibody, inhibits eosinophil activation, but real-world evidence for its efficacy and safety in ANCA-negative EGPA is insufficient.
To summarize clinical features of ANCA-negative EGPA patients and evaluate the real-world efficacy and safety of mepolizumab by combining objective indicators (peripheral blood eosinophil [EOS] count, pulmonary function) and subjective scores (ACT, BVAS).
Eight ANCA-negative EGPA patients treated with mepolizumab (300 mg subcutaneously, q4w, ≥6 cycles) in our hospital from January 2024 to July 2025 were retrospectively enrolled. Baseline and follow-up data were collected. SPSS 25.0 was used to analyze changes in EOS count, ACT/BVAS scores, clinical symptoms, corticosteroid dosage and pulmonary function before and after treatment, with Wilcoxon test for comparisons.
Among 8 patients (5 females, median age 54 years), 62.5% had asthma and chronic sinusitis, 37.5% hyposmia/anosmia, and 87.5% used systemic corticosteroids at baseline. Baseline pulmonary function showed mean FEV1% pred 54.41%, FEV1/FVC 63.11%, DLCo% pred 80.34%, with obstructive ventilation dysfunction on chest CT. All patients had elevated baseline EOS (median 1.03×10⁹/L), and 87.5% had increased IgE. After 2-3 cycles, mean EOS decreased to 0.026×10⁹/L (P=0.012). Pulmonary function improved significantly (FEV1% pred 67.03%, FEV1/FVC 67.88%, DLCo% pred 94.22%). Acute exacerbations reduced markedly; nasal symptoms and hyposmia were relieved, and all steroid users achieved dosage reduction or discontinuation. At 12 weeks, mean ACT score rose to 15.62 (P=0.012), and 87.5% had stable or decreased BVAS scores. No new safety signals were found, and elderly patients with comorbidities had good drug tolerance.
Mepolizumab rapidly and potently inhibits eosinophil levels in ANCA-negative EGPA patients, improves clinical symptoms and pulmonary function, controls disease activity, and effectively reduces corticosteroid dosage with favorable safety. It is an optimal targeted therapy for ANCA-negative EGPA patients with poor conventional treatment response, steroid dependence or contraindications, and is of great clinical significance for improving long-term prognosis.